Precision BioSciences/$DTIL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Precision BioSciences
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Ticker
$DTIL
Sector
Primary listing
Employees
68
Headquarters
Website
DTIL Metrics
BasicAdvanced
$149M
-
-$3.56
1.32
-
Price and volume
Market cap
$149M
Beta
1.32
52-week high
$8.82
52-week low
$3.53
Average daily volume
310K
Financial strength
Current ratio
13.322
Quick ratio
12.968
Long term debt to equity
29.595
Total debt to equity
31.229
Interest coverage (TTM)
-36.67%
Profitability
EBITDA (TTM)
-50.68
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-133.45%
Operating margin (TTM)
-152.19%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
-22.42%
Return on equity (TTM)
-62.71%
Valuation
Price to revenue (TTM)
2.253
Price to book
1.57
Price to tangible book (TTM)
1.59
Price to free cash flow (TTM)
-1.16
Free cash flow yield (TTM)
-86.18%
Free cash flow per share (TTM)
-5.188
Growth
Revenue change (TTM)
-50.12%
Earnings per share change (TTM)
-442.78%
3-year revenue growth (CAGR)
10.93%
3-year earnings per share growth (CAGR)
-54.60%
What the Analysts think about DTIL
Analyst ratings (Buy, Hold, Sell) for Precision BioSciences stock.
DTIL Financial Performance
Revenues and expenses
DTIL Earnings Performance
Company profitability
DTIL News
AllArticlesVideos
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
Business Wire·2 weeks ago
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
Business Wire·3 weeks ago
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Precision BioSciences stock?
Precision BioSciences (DTIL) has a market cap of $149M as of March 29, 2026.
What is the P/E ratio for Precision BioSciences stock?
The price to earnings (P/E) ratio for Precision BioSciences (DTIL) stock is 0 as of March 29, 2026.
Does Precision BioSciences stock pay dividends?
No, Precision BioSciences (DTIL) stock does not pay dividends to its shareholders as of March 29, 2026.
When is the next Precision BioSciences dividend payment date?
Precision BioSciences (DTIL) stock does not pay dividends to its shareholders.
What is the beta indicator for Precision BioSciences?
Precision BioSciences (DTIL) has a beta rating of 1.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.